Dagens Industri SV

Sobi-partner sänker priset på läkemedel med 93 procent

Specialistläkemedelsbolaget Sobis partner Ionis Pharmaceuticals sänker inför en förväntad utökad indikation för det blodfettssänkande läkemedlet Tryngolza (olezarsen) priset med 93 procent.

Mar 26, 2026 &03292626202631; 07:29 UTC www.di.se Trending 2/5

Read original on www.di.se ↗

↘

Negative for markets

Sentiment score: -65/100

High impact Short-term (days)

WHAT THIS MEANS

Ionis Pharmaceuticals, partner of Swedish biotech Sobi, dramatically cuts Tyngolza (olezarsen) price by 93% ahead of expanded indication approval. This aggressive pricing move signals confidence in label expansion but creates significant revenue headwinds for Sobi, which depends on this partnership.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

SOBI.ST

SOBI.STStock

Expected to decline

93% price cut on key partnership drug (Tyngolza) severely impacts revenue per unit. While volume expansion is possible with lower price, the immediate margin compression and cash flow impact outweighs upside. Market will likely punish near-term earnings guidance.

⇅

S&P 500

^GSPCIndex

High volatility expected

Broader biotech sector mixed signals: aggressive pricing for access is positive long-term but signals margin pressure across specialty pharma. VIX already elevated (+4.07%), suggesting risk-off sentiment dominates.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

SHORT Sobi on this news; the 93% price cut is a material negative for near-term cash flow and guidance, despite long-term volume upside. Risk/reward favors downside in current risk-off environment (elevated VIX). Set stop above 5% if wrong. [MOVE:-2.5%]

KEY SIGNALS

93% price reduction = severe revenue headwind despite volume potentialTyngolza is core Sobi asset; partnership economics now materially worseExpanded indication approval expected (positive) but pricing power destroyed (negative)VIX elevated; risk-off environment amplifies negative biotech sentimentNews is fresh (11 min) and unexpected — market has NOT yet repriced Sobi

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 26, 2026 at 07:40 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Dagens Industri. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Sobi-partner sänker priset på läkemedel med 93 procent

RELATED INTELLIGENCE